Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS
Interventions: DRUG: Tucatinib
Sponsor: Seagen Inc.